While medicinal inorganic chemistry has been practised for over 5000 years, it was not until
the late 1800s when Alfred Werner published his ground-breaking research on coordination …

The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer,
but new platinum agents have been very slow to enter the clinic. Recently, however, there …

Encouraged by the worldwide success of cisplatin in the field of cancer chemotherapy,
intensive works have been conducted to explore more platinum coordination complexes as …

Breast cancer (BC) is one of the most common malignancies in women and often
accompanied by inflammatory processes. Cyclooxygenase‐2 (COX‐2) plays a vital role in …

In this manuscript we focus on Pt (IV) anticancer prodrugs. We explore the main working
hypotheses for the design of effective Pt (IV) prodrugs and note the exceptions to the …

Drug resistance remains the major cause of cancer treatment failure especially at the late
stage of the disease. However, based on their versatile chemistry, metal and metalloid …

Pt (IV) complexes act as prodrugs that are activated inside cancer cells releasing cytotoxic Pt
(II) drugs such as cisplatin as well as two axial ligands. These ligands can be used to confer …

Platinum-based anticancer drugs dominate the chemotherapy field for several cancers, but
problems such as systemic toxicity and acquired resistance for some primary tumors hamper …

Pt (IV) complexes are designed as prodrugs that are intended to overcome resistance. Pt
(IV) prodrugs are activated inside cancer cells releasing cytotoxic Pt (II) drugs as well as two …

Although multitargeted PtIV anticancer prodrugs have shown significant activities in
reducing drug resistance, the types of bioactive ligands and drugs that can be conjugated to …